Published in Arthritis Rheum on May 01, 2010
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) (2011) 0.91
Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis (2011) 0.79
Recent clinical trials in lupus nephritis. Rheum Dis Clin North Am (2014) 0.78
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler (2011) 0.78
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. Am J Blood Res (2013) 0.75
Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study. BMC Womens Health (2011) 0.75
High-dose chemotherapy and multiple sclerosis. Curr Opin Oncol (2011) 0.75
Stem cell therapy: resetting autoimmunity or postponing the inevitable? Ther Adv Musculoskelet Dis (2011) 0.75
High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med (2000) 4.99
Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum (1985) 2.85
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA (2006) 2.34
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med (1988) 1.53
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med (1998) 1.51
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50
Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum (2005) 1.46
Autologous stem cell transplantation for systemic lupus erythematosus. Lupus (2004) 1.24
Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood (1996) 1.16
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum (2003) 1.02
High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus (2002) 0.83
Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol (1998) 0.82
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A (2005) 4.64
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol (2007) 2.81
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood (2012) 2.72
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol (2009) 2.33
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg (2002) 2.12
Aplastic anaemia. Lancet (2005) 2.10
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res (2009) 1.92
Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol (2010) 1.89
Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) (2006) 1.87
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant (2003) 1.81
Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation (2008) 1.80
Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol (2003) 1.75
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2013) 1.68
Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl (2009) 1.65
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
The paradox of response and survival in cancer therapeutics. Blood (2005) 1.63
The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum (2005) 1.59
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol (2004) 1.58
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma (2012) 1.57
The SEEK model of pediatric primary care: can child maltreatment be prevented in a low-risk population? Acad Pediatr (2012) 1.56
Intrafamilial transmission of hepatitis C in Egypt. Hepatology (2005) 1.53
Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A (2004) 1.49
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma (2011) 1.49
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol (2006) 1.48
Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.45
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res (2008) 1.43
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol (2005) 1.41
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2009) 1.41
Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes. Eur J Haematol (2014) 1.41
The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. Am J Hum Genet (2012) 1.40
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum (2012) 1.34
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol (2010) 1.33
Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins. Cell Stem Cell (2008) 1.32
Identifying children at high risk for a child maltreatment report. Child Abuse Negl (2011) 1.29
Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics (2008) 1.29
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis (2012) 1.29
Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2004) 1.28
PIG-A mutations in normal hematopoiesis. Blood (2005) 1.27
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med (2007) 1.24
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res (2007) 1.23
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood (2012) 1.23
A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics (2005) 1.22
Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol (2002) 1.21
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol (2002) 1.20
Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One (2010) 1.19
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology (2013) 1.18
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2010) 1.18
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant (2011) 1.17
High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood (2002) 1.17
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry (2002) 1.16
Characterization of chronic myeloid leukemia stem cells. Am J Hematol (2011) 1.15
ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J Virol (2007) 1.14
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant (2013) 1.13
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2006) 1.12
Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans R Soc Trop Med Hyg (2008) 1.12
Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci (2008) 1.10
Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant (2009) 1.10
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep (2011) 1.07
Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget (2013) 1.07
Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol (2009) 1.05
Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. Clin Infect Dis (2010) 1.04
Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proc Natl Acad Sci U S A (2013) 1.04
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One (2010) 1.04
Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect Agent Cancer (2010) 1.04
Gender disparity in liver transplant waiting-list mortality: the importance of kidney function. Liver Transpl (2010) 1.03
Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol (2012) 1.03
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum (2003) 1.02